Sarah B. Goldberg on New Immunotherapy Options for Patients With Lung Cancer

April 13, 2016
Sarah B. Goldberg, MD, MPH

Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).

Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).

The FDA has approved two immunotherapy agents for NSCLC, nivolumab (Opdivo) and pembrolizumab (Keytruda) as an option for patients who already received one line of chemotherapy that did not work. These two agents work by blocking the PD-1 pathway, which lets the patient's immune system attack the cancer.